IAPs and RIPK1 mediate LPS-induced cytokine production in healthy subjects and Crohn's disease

Research output: Contribution to journalJournal articleResearchpeer-review

Innate immune activity fuels intestinal inflammation in Crohn's disease (CD), an inflammatory bowel disease (IBD). Identification and targeting of new molecular regulators of the innate activity are warranted to control the disease. Inhibitor of apoptosis proteins (IAPs) regulate both cell survival and inflammatory signaling. We investigated effects of IAP inhibition by second mitochondria-derived activator of caspases (SMAC) mimetics (SMs) on innate responses and cell death to pathogen-associated molecular patterns in peripheral blood mononuclear cells (PBMCs) and monocytes. IAPs inhibited lipopolysaccharide (LPS)-induced expression of proinflammatory interleukin (IL)-1β, IL-6. Likewise, LPS (but not muramyl dipeptide or E. coli) induced TNF-α was inhibited in CD and control PBMCs. The SM effect was partially reversed by inhibition of receptor-interacting serine/threonine-protein kinase 1 (RIPK1). The effect was mainly cell death independent. Thus, IAP inhibition by SMs leads to reduced production of proinflammatory cytokines and may be considered in the efforts to develop new therapeutic strategies to control CD.

Original languageEnglish
JournalClinical and Experimental Immunology
Volume215
Issue number3
Pages (from-to)291–301
Number of pages11
ISSN0009-9104
DOIs
Publication statusPublished - 2024

Bibliographical note

© The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Immunology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

ID: 364502173